JACC This Week · American College of Cardiology

Amyloidosis in Focus: Biomarkers, Structural Insights & Therapeutic Strategy | JACC This Week

·15 min·1 clip

Harlan Krumholz reveals that new amyloid drugs cost up to $500,000 a year, challenging us to make them accessible.

This episode of JACC This Week focuses on a mini-issue about amyloid heart disease, covering biomarkers, structural insights, and therapeutic strategies, including discussions on high drug costs, negative trial results for vasovagal syncope, and DOACs vs warfarin in frail elderly patients. It highlights advances in amyloidosis treatment and the importance of access and evidence-based care.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from JACC This Week